Designing metal-contained enzyme mimics for prodrug activation

Stimuli-responsive prodrugs with self-immolative linker for improved cancer therapy

Self-immolative prodrugs have gained significant attention as an innovative approach for targeted cancer therapy. These prodrugs are engineered to release the active anticancer agents in response to specific triggers within the tumor microenvironment, thereby improving therapeutic precision while reducing systemic toxicity. This review focuses on the molecular architecture and design principles of self-immolative prodrugs, emphasizing the role of stimuli-responsive linkers and activation mechanisms that enable controlled drug release. Recent advancements in this field include the development of prodrugs that incorporate targeting moieties for enhanced site-specificity. Moreover, the review discusses the incorporation of targeting moieties to achieve site-specific drug delivery, thereby improving the selectivity of treatment. By summarizing key research from the past five years, this review highlights the potential of self-immolative prodrugs to revolutionize cancer treatment strategies and pave the way for their integration into clinical practice.

The recent research progress in the application of the nanozyme-hydrogel composite system for drug delivery

Hydrogels, comprising 3D hydrophilic polymer networks, have emerged as promising biomaterial candidates for emulating the structure of biological tissues and delivering drugs through topical administration with good biocompatibility. Nanozymes can catalyze endogenous biomolecules, thereby initiating or inhibiting in vivo biological processes. A nanozyme-hydrogel composite inherits the biological functions of hydrogels and nanozymes, where the nanozyme serves as the catalytic core and the hydrogel forms the structural scaffold. Moreover, the composite can concentrate nanozymes in targeted lesions and catalyze the binding of a specific group of substrates, resulting in pathological microenvironment remodeling and drug-penetrating barrier impairment. The composite also shields nanozymes to prevent burst release during catalytic production and reduce related toxicity. Currently, the application of these composites has been extended to antibacterial, anti-inflammatory, anticancer, and tissue repair applications. In this review, we elucidate the preparation methods for nanozyme-hydrogel composites, provide compelling evidence of their advantages in drug delivery and provide a comprehensive overview of their biological application.

Bioorthogonal chemistry-based prodrug strategies for enhanced biosafety in tumor treatments: current progress and challenges

Cancer is a significant global health challenge, and while chemotherapy remains a widely used treatment, its non-specific toxicity and broad distribution can lead to systemic side effects and limit its effectiveness against tumors. Therefore, the development of safer chemotherapy alternatives is crucial. Prodrugs hold great promise, as they remain inactive until they reach the cancer site, where they are selectively activated by enzymes or specific factors, thereby reducing side effects and improving targeting. However, subtle differences in the microenvironments between tumors and normal tissue may still result in unintended cytotoxicity. Bioorthogonal reactions, known for their selectivity and precision without interfering with natural biochemical processes, are gaining attention. When combined with prodrug strategies, these reactions offer the potential to create highly effective chemotherapy drugs. This review examines the safety and efficacy of prodrug strategies utilizing various bioorthogonal reactions in cancer treatment.

Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications

A central paradigm of cardiovascular homeostasis is that impaired nitric oxide (NO) bioavailability results in a wide array of cardiovascular dysfunction including incompetent endothelium-dependent vasodilatation, thrombosis, vascular inflammation, and proliferation of the intima. Over the course of more than a century, NO donating formulations such as organic nitrates and nitrites have remained a cornerstone of treatment for patients with cardiovascular diseases. These donors primarily produce NO in the circulation and are not targeted to specific (sub)cellular sites of action. However, safe, and therapeutic levels of NO require delivery of the right amount to a precise location at the right time. To achieve these aims, several recent strategies aimed at therapeutically generating or releasing NO in living systems have shown that polymeric and inorganic (silica, gold) nanoparticles and nanoscale metal-organic frameworks could either generate NO endogenously by the catalytic decomposition of endogenous NO substrates or can store and release therapeutically relevant amounts of NO gas. NO-releasing nanomaterials have been developed for vascular implants (such as stents and grafts) to target atherosclerosis, hypertension, myocardial ischemia-reperfusion injury, and cardiac tissue engineering. In this review, we discuss the advances in design and development of novel NO-releasing nanomaterials for cardiovascular therapeutics and critically examine the therapeutic potential of these nanoplatforms to modulate cellular metabolism, to regulate vascular tone, inhibit platelet aggregation, and limit proliferation of vascular smooth muscle with minimal toxic effects.

Supramolecular Hydrolase Mimics in Equilibrium and Kinetically Trapped States

The folding of proteins into intricate three-dimensional structures to achieve biological functions, such as catalysis, is governed by both kinetic and thermodynamic controls. The quest to design artificial enzymes using minimalist peptides seeks to emulate supramolecular structures existing in a catalytically active state. Drawing inspiration from the nuanced process of protein folding, our study explores the enzyme-like activity of amphiphilic peptide nanosystems in both equilibrium and non-equilibrium states, featuring the formation of supramolecular nanofibrils and nanosheets. In contrast to thermodynamically stable nanosheets, the kinetically trapped nanofibrils exhibit dynamic characteristics (e.g., rapid molecular exchange and relatively weak intermolecular packing), resulting in a higher hydrolase-mimicking activity. We emphasize that a supramolecular microenvironment characterized by an optimal local polarity, microviscosity, and β-sheet hydrogen bonding is conducive to both substrate binding and ester bond hydrolysis. Our work underscores the pivotal role of both thermodynamic and kinetic control in impacting biomimetic catalysis and sheds a light on the development of artificial enzymes.

Nanoreactor-based catalytic systems for therapeutic applications: Principles, strategies, and challenges

Inspired by natural catalytic compartments, various synthetic compartments that seclude catalytic reactions have been developed to understand complex multistep biosynthetic pathways, bestow therapeutic effects, or extend biosynthetic pathways in living cells. These emerging nanoreactors possessed many advantages over conventional biomedicine, such as good catalytic activity, specificity, and sustainability. In the past decade, a great number of efficient catalytic systems based on diverse nanoreactors (polymer vesicles, liposome, polymer micelles, inorganic-organic hybrid materials, MOFs, etc.) have been designed and employed to initiate in situ catalyzed chemical reactions for therapy. This review aims to present the recent progress in the development of catalytic systems based on nanoreactors for therapeutic applications, with a special emphasis on the principles and design strategies. Besides, the key components of nanoreactor-based catalytic systems, including nanocarriers, triggers or energy inputs, and products, are respectively introduced and discussed in detail. Challenges and prospects in the fabrication of therapeutic catalytic nanoreactors are also discussed as a conclusion to this review. We believe that catalytic nanoreactors will play an increasingly important role in modern biomedicine, with improved therapeutic performance and minimal side effects.

Progress in controllable bioorthogonal catalysis for prodrug activation

Bioorthogonal catalysis, a class of catalytic reactions that are mediated by abiotic metals and proceed in biological environments without interfering with native biochemical reactions, has gained ever-increasing momentum in prodrug delivery over the past few decades. Albeit great progress has been attained in developing new bioorthogonal catalytic reactions and optimizing the catalytic performance of transition metal catalysts (TMCs), the use of TMCs to activate chemotherapeutics at the site of interest in vivo remains a challenging endeavor. To translate the bioorthogonal catalysis-mediated prodrug activation paradigm from flasks to animals, TMCs with targeting capability and stimulus-responsive behavior have been well-designed to perform chemical transformations in a controlled manner within highly complex biochemical systems, rendering on-demand drug activation to mitigate off-target toxicity. Here, we review the recent advances in the development of controllable bioorthogonal catalysis systems, with an emphasis on different strategies for engineering TMCs to achieve precise control over prodrug activation. Furthermore, we outline the envisaged challenges and discuss future directions of controllable bioorthogonal catalysis for disease therapy.

Dye Doped Metal-Organic Frameworks for Enhanced Phototherapy

Phototherapy is a noninvasive cancer treatment that relies on the interaction between light and photoactive agents. These photoactive agents are typically organic dyes, but their hydrophobic nature and self-aggregation tendency in biological media greatly restricts the development of highly effective phototherapeutic systems. In the past decade, functional dye-doped metal-organic framework (MOF)-based phototherapy has attracted enormous interest because organic dyes can be encapsulated and isolated within the MOF structure to show superior treatment efficacy. In addition to incorporating the reported phototherapeutic dyes into MOF as the ligand or the guest in the pores, the construction of an MOF-based phototherapy agent can also be extended to these dye units that are previously inactive for phototherapy. Thus, this review focuses on the emerging development of phototherapeutic MOFs that exhibited better performance than the involving dye units due to the controlled dye aggregation within the MOF. The related mechanisms and some emerging future directions of dye-doped MOF-based phototherapy are also discussed and summarized.

Near-Infrared-II Plasmonic Trienzyme-Integrated Metal-Organic Frameworks with High-Efficiency Enzyme Cascades for Synergistic Trimodal Oncotherapy

Natural enzyme-based catalytic cascades hold great promise for cancer therapy, but their clinical utility is greatly hindered by the loss of their functions during in vivo delivery. Herein, a plasmonic trienzyme-integrated metal-organic framework (plasEnMOF) nanoplatform with high-efficiency enzyme cascades is reported for synergistic starvation, chemodynamic, and plasmonic hyperthermia trimodal therapy of hypoxic tumors. These plasEnMOFs are created with encapsulation of near-infrared-II (NIR-II) plasmonic Au nanorods and natural enzymes-catalase (CAT), glucose oxidase (GOx), and horseradish peroxidase (HRP) within zeolitic imidazolate framework-8 (ZIF-8) MOFs. As a trienzyme cascade system, the plasEnMOFs effectively deplete intratumoral glucose and generate toxic reactive oxygen species (ROS) for starvation therapy and chemodynamic therapy (CDT) combined with the plasmonic hyperthermia therapy (PHT). The enhanced glucose consumption and ROS generation by the NIR-II plasmonic photothermal effect are also demonstrated. The improved chemo- and thermotolerance of the encapsulated natural enzymes within the protective ZIF-8 MOFs are evidenced. With the integrated enzyme cascades and NIR-II photothermal effects, these plasEnMOFs are demonstrated with exceptional therapeutic effects on 4T1 xenograft tumors through the combined starvation/CDT/PHT therapy. This work highlights the superiority of natural enzyme cascade systems integrated in plasmonic MOFs for high-efficiency enzymatic cancer therapy.

Iron Phosphate Nanozyme-Hydrogel with Multienzyme-like Activity for Efficient Bacterial Sterilization

Pathogenic bacteria infections have posed a threat to human health worldwide. Nanomaterials with natural enzymatic activity provide an opportunity for the development of new antibacterial pathways. We successfully constructed iron phosphate nanozyme-hydrogel (FePO₄-HG) with the traits of positive charge and macropores. Interestingly, FePO₄-HG displayed not only peroxidase-like activity under acidic bacterial infectious microenvironment but also superoxide dismutase-catalase-like synergistic effects in neutral or weak alkaline conditions, thus protecting normal tissues from the peroxidase-like protocol with exogenous H₂O₂ damage. Furthermore, the positive charge and macropore structure of FePO₄-HG could capture and restrict bacteria in the range of ROS destruction. Obviously, FePO₄-HG exhibited excellent antibacterial ability against MRSA and AREC with the assistance of H₂O₂. Significantly, the FePO₄-HG + H₂O₂ system could efficiently disrupt the bacterial biofilm formation and facilitate the glutathione oxidation process to rapid bacterial death with low cytotoxicity. Moreover, FePO₄-HG was unsusceptible to bacterial resistance development in MRSA. Animal experiments showed that the FePO₄-HG + H₂O₂ group could efficiently eliminate the MRSA infection and present excellent wound healing without inflammation and tissue adhesions. With further development and optimization, FePO₄-HG has great potential as a new class of antibacterial agents to fight antibiotic-resistant pathogens.

Stimulus-responsive self-assembled prodrugs in cancer therapy

Small-molecule prodrugs have become the main toolbox to improve the unfavorable physicochemical properties of potential therapeutic compounds in contemporary anti-cancer drug development. Many approved small-molecule prodrugs, however, still face key challenges in their pharmacokinetic (PK) and pharmacodynamic (PD) properties, thus severely restricting their further clinical applications. Self-assembled prodrugs thus emerged as they could take advantage of key benefits in both prodrug design and nanomedicine, so as to maximize drug loading, reduce premature leakage, and improve PK/PD parameters and targeting ability. Notably, temporally and spatially controlled release of drugs at cancerous sites could be achieved by encoding various activable linkers that are sensitive to chemical or biological stimuli in the tumor microenvironment (TME). In this review, we have comprehensively summarized the recent progress made in the development of single/multiple-stimulus-responsive self-assembled prodrugs for mono- and combinatorial therapy. A special focus was placed on various prodrug conjugation strategies (polymer-drug conjugates, drug-drug conjugates, etc.) that facilitated the engineering of self-assembled prodrugs, and various linker chemistries that enabled selective controlled release of active drugs at tumor sites. Furthermore, some polymeric nano-prodrugs that entered clinical trials have also been elaborated here. Finally, we have discussed the bottlenecks in the field of prodrug nanoassembly and offered potential solutions to overcome them. We believe that this review will provide a comprehensive reference for the rational design of effective prodrug nanoassemblies that have clinic translation potential.

Exploration of nanozymes in viral diagnosis and therapy

Nanozymes are nanomaterials with similar catalytic activities to natural enzymes. Compared with natural enzymes, they have numerous advantages, including higher physiochemical stability, versatility, and suitability for mass production. In the past decade, the synthesis of nanozymes and their catalytic mechanisms have advanced beyond the simple replacement of natural enzymes, allowing for fascinating applications in various fields such as biosensing and disease treatment. In particular, the exploration of nanozymes as powerful toolkits in diagnostic viral testing and antiviral therapy has attracted growing attention. It can address the great challenges faced by current natural enzyme-based viral testing technologies, such as high cost and storage difficulties. Therefore, nanozyme can provide a novel nanozyme-based antiviral therapeutic regime with broader availability and generalizability that are keys to fighting a pandemic such as COVID-19. Herein, we provide a timely review of the state-of-the-art nanozymes regarding their catalytic activities, as well as a focused discussion on recent research into the use of nanozymes in viral testing and therapy. The remaining challenges and future perspectives will also be outlined. Ultimately, this review will inform readers of the current knowledge of nanozymes and inspire more innovative studies to push forward the frontier of this field.

Nanomaterial-based bioorthogonal nanozymes for biological applications

Bioorthogonal transformations are chemical reactions that use pathways which biological processes do not access. Bioorthogonal chemistry provides new approaches for imaging and therapeutic strategies, as well as tools for fundamental biology. Bioorthogonal catalysis enables the development of bioorthogonal "factories" for on-demand and in situ generation of drugs and imaging tools. Transition metal catalysts (TMCs) are widely employed as bioorthogonal catalysts due to their high efficiency and versatility. The direct application of TMCs in living systems is challenging, however, due to their limited solubility, instability in biological media and toxicity. Incorporation of TMCs into nanomaterial scaffolds can be used to enhance aqueous solubility, improve long-term stability in biological environment and minimize cytotoxicity. These nanomaterial platforms can be engineered for biomedical applications, increasing cellular uptake, directing biodistribution, and enabling active targeting. This review summarizes strategies for incorporating TMCs into nanomaterial scaffolds, demonstrating the potential and challenges of moving bioorthogonal nanocatalysts and nanozymes toward the clinic.

Porous Oxyhydroxide Derived from Metal-Organic Frameworks as Efficient Triphosphatase-like Nanozyme for Chromium(III) Ion Colorimetric Sensing

The dephosphorylation that involves the removal of a phosphate group from a substrate molecule plays a significant role in living organisms. An enzyme mimic (nanozyme) with phosphatase-like catalytic activity has recently received attention in terms of its capacity for dephosphorylation. In this study, three types of highly porous oxyhydroxide with remarkable triphosphatase-like catalytic activities, ZrOOH, GdOOH, and HfOOH, have been prepared through the transformation of metal-organic frameworks (MOFs) using a simple alkaline hydrolysis method. The triphosphatase mimetic activities of ZrOOH, GdOOH, and HfOOH were then thoroughly investigated and verified. In particular, an isotopic tracing experiment revealed that abundant surface hydroxyls could serve as nucleophilic agents to directly attack the electropositive phosphorus atom, causing the cleavage of the terminal phosphoester bonds of phosphoester substrate molecules. The kinetic analysis provided calculated values of K_m of 105.7, 90.5, and 46.1 μM, while the V_max values were 3.57, 4.76, and 2.74 × 10^-8 M s^-1 and E_a values were estimated to be 47.52, 41.15, and 52.79 kJ/mol for ZrOOH, GdOOH, and HfOOH, respectively. The chromium(III) ions acting as "poisoning" inhibitors efficiently downregulated the triphosphatase mimetic activity of GdOOH. On the basis of this effect, a colorimetric chromium(III) ion-sensing system was explored, which provided a relevant linear response range for the detection of chromium(III) ions of 5.0-200 μM and a low detection limit of 0.84 μM. This work not only shows the great potential of ZrOOH, GdOOH, and HfOOH as triphosphatase nanozymes but also deepens our understanding of the role of surface hydroxyls on phosphatase-mimicking nanozyme catalytic dephosphorization, which could be used in the rational design of phosphatase-mimicking nanozymes. Furthermore, the developed colorimetric sensing system could be applied to chromium(III) ion detection in biological systems.

Clip Chemistry: Diverse (Bio)(macro)molecular and Material Function through Breaking Covalent Bonds

In the two decades since the introduction of the "click chemistry" concept, the toolbox of "click reactions" has continually expanded, enabling chemists, materials scientists, and biologists to rapidly and selectively build complexity for their applications of interest. Similarly, selective and efficient covalent bond breaking reactions have provided and will continue to provide transformative advances. Here, we review key examples and applications of efficient, selective covalent bond cleavage reactions, which we refer to herein as "clip reactions." The strategic application of clip reactions offers opportunities to tailor the compositions and structures of complex (bio)(macro)molecular systems with exquisite control. Working in concert, click chemistry and clip chemistry offer scientists and engineers powerful methods to address next-generation challenges across the chemical sciences.

Ceria Nanozyme and Phosphate Prodrugs: Drug Synthesis through Enzyme Mimicry

Nanozymes can mimic the activities of diverse enzymes, and this ability finds applications in analytical sciences and industrial chemistry, as well as in biomedical applications. Among the latter, prodrug conversion mediated by nanozymes is investigated as a step toward site-specific drug synthesis, to achieve localized therapeutic effects. In this work, we investigated a ceria nanozyme as a mimic to phosphatase, to mediate conversion of phosphate prodrugs into corresponding therapeutics. To this end, the substrate scope of ceria as a phosphatase mimic was analyzed using a broad range of natural phosphor(di)esters and pyrophosphates. Knowledge of this scope guided the selection of existing phosphate prodrugs that can be converted by ceria into the corresponding therapeutics. "Extended scaffold phosphates" were engineered using self-immolative linkers to accommodate a prodrug design for amine-containing drugs, such as monomethyl auristatin E. Phosphate prodrugs masked activity of the toxin, whereas prodrug conversion mediated by the nanozyme restored drug toxicity, which was validated in mammalian cell culture. The main novelty of this work lies in the rational pairing of the ceria nanozyme with the existing and the de novo designed "extended scaffold" phosphate prodrugs toward their use in nanozyme-prodrug therapy based on the defined nanozyme substrate scope.

Versatile labeling of multiple radionuclides onto a nanoscale metal-organic framework for tumor imaging and radioisotope therapy

Radionuclides for cancer theranostic have confronted problems such as limitation in real-time visualization and unsatisfactory therapeutic effect sacrificed by the nonspecific distribution. Nanoscale metal-organic frameworks (nMOFs) have been widely used in biomedical applications including cancer imaging and drug delivery. However, there have been rare reports utilizing nMOFs as a single nanoplatform to label various radionuclides for tumor imaging and radioisotope therapy (RIT). In this work, we developed polyethylene glycol (PEG) modified zirconium-based nMOFs (PCN-224) with favorable size, water solubility and biocompatibility. Interestingly, without the help of chelating agents, metal radionuclides (technetium-99 m/^99mTc, lutetium-177/¹⁷⁷Lu) could be efficiently labeled onto nMOFs via chelating with the porphyrin structure and iodine-125 (¹²⁵I) via chemical substitution of hydrogen in the benzene ring. The radionuclide-labeled PCN-PEG nanoparticles all exhibit excellent radiolabeling stability in different solutions. In accordance with the fluorescence imaging of mice injected with PCN-PEG, SPECT/CT imaging illustrates strong tumor accumulation of ^99mTc-PCN-PEG. Moreover, ¹⁷⁷Lu-PCN-PEG significantly inhibited the growth of tumor without inducing any perceptible toxicity to the treated mice. Hence, the radionuclide-delivery nanoplatform based on nMOFs would provide more opportunities for precise tumor theranostics and expand the biomedical applications of MOF nanomaterials.

The Role of Nanomaterials in Modulating the Structure and Function of Biomimetic Catalysts

Nanomaterial-incorporated enzyme mimics have so far been examined in various cases, and their properties are governed by the properties of both catalysts and materials. This review summarizes recent efforts in understanding the role of inorganic nanomaterials for modulating biomimetic catalytic performance. Firstly, the importance of enzyme mimics, and the necessity for tuning their catalysis will be outlined. Based on structural characteristics, these catalysts are divided into two types: traditional artificial enzymes, and novel nanomaterial-based enzyme mimics. Secondly, the mechanisms on how nano-sized materials interact with these catalysts will be examined. Intriguingly, incorporating various nanomaterials into biomimetic catalysts may provide a convenient and highly efficient method for the modulation of activities as well as stabilities or introduce new and attractive features. Finally, the perspectives of the main challenges and future opportunities in the areas of nanomaterial-incorporated biomimetic catalysis will be discussed. In this regard, nanomaterials as a kind of promising scaffold for tuning catalysis will attract more and more attention and be practically applied in numerous fields.

Nanozymes and Glucuronides: Glucuronidase, Esterase, and/or Transferase Activity

Nanozymes are fundamentally interesting catalysts that are investigated as alternatives to fragile protein-enzymes for applications in biotechnology, for prodrug activation, and use in biomedicine, as well as the catalysts that contributed to the Origin of Life. However, until now, nanozymes mostly have been documented to exhibit activity as red/ox catalysts, whereas examples of activity outside this broad class of reactions are very few. Herein, activity of nanozymes on glucuronide prodrugs is investigated, specifically focusing on the mechanism of prodrug conversion reactions. The main finding of this work is that nanozymes exhibit glucuronide-like activity, but also catalyze prodrug conversion via esterase-like mechanism and facilitate group transfer reactions.

Enzyme Mimics for the Catalytic Generation of Nitric Oxide from Endogenous Prodrugs

The highly diverse biological roles of nitric oxide (NO) in both physiological and pathophysiological processes have prompted great interest in the use of NO as a therapeutic agent in various biomedical applications. NO can exert either protective or deleterious effects depending on its concentration and the location where it is delivered or generated. This double-edged attribute, together with the short half-life of NO in biological systems, poses a major challenge to the realization of the full therapeutic potential of this molecule. Controlled release strategies show an admirable degree of precision with regard to the spatiotemporal dosing of NO but are disadvantaged by the finite NO deliverable payload. In turn, enzyme-prodrug therapy techniques afford enhanced deliverable payload but are troubled by the inherent low stability of natural enzymes, as well as the requirement to control pharmacokinetics for the exogenous prodrugs. The past decade has seen the advent of a new paradigm in controlled delivery of NO, namely localized bioconversion of the endogenous prodrugs of NO, specifically by enzyme mimics. These early developments are presented, successes of this strategy are highlighted, and possible future work on this avenue of research is critically discussed.

Efficient enzyme-activated therapy based on the different locations of protein and prodrug in nanoMOFs

Enzyme-activated prodrug therapy (EAPT) is an effective cancer treatment strategy able to transport non-toxic prodrugs and subsequently convert them into drugs at specific times and locations. However, due to the limitation of easy biodegradability and the membrane-impermeable characteristic of exogenous enzymes, there is a need to exploit suitable carriers for the effective protection and simultaneous delivery of activating enzymes into cancer cells. Herein, hierarchically porous MOFs were employed for the loading of enzyme and prodrug in a single nanocarrier thanks to their different cavity sizes. The simple loading process allows entrapping of horseradish peroxidase (HRP) and a monocarboxyl-containing indole-3-acetic acid (IAA) prodrug with high loading capacities in different spaces, which keeps the catalytic activity of the enzyme perfectly intact and avoids the premature activation of the prodrug. The encapsulated HRP and IAA exhibit sustained and synchronized release behaviors. Compared to the native HRP enzyme, the current MOF nanocarriers not only facilitate enzyme delivery into cellular lysosomes and subsequent endosomal escape, but also effectively release enzyme and prodrug in the intracellular environment within 48 h. Eventually, HRP and IAA loaded MOF nanocarriers cause significant cell death with a low IC₅₀ of 4.2 mg L^-1, while the IAA prodrug alone is non-toxic even at high concentrations. Thus, hierarchically porous MOFs might offer a promising platform for EAPT with a highly consistent spatiotemporal distribution of enzymes and prodrugs in target tissues.

Intracellular Catalysis with Selected Metal Complexes and Metallic Nanoparticles: Advances toward the Development of Catalytic Metallodrugs

Platinum-containing drugs (e.g., cisplatin) are among the most frequently used chemotherapeutic agents. Their tremendous success has spurred research and development of other metal-based drugs, with notable achievements. Generally, the vast majority of metal-based drug candidates in clinical and developmental stages are stoichiometric agents, i.e., each metal complex reacts only once with their biological target. Additionally, many of these metal complexes are involved in side reactions, which not only reduce the effective amount of the drug but may also cause toxicity. On a separate note, transition metal complexes and nanoparticles have a well-established history of being potent catalysts for selective molecular transformations, with examples such as the Mo- and Ru-based catalysts for metathesis reactions (Nobel Prize in 2005) or palladium catalysts for C-C bond forming reactions such as Heck, Negishi, or Suzuki reactions (Nobel Prize in 2010). Also, notably, no direct biological equivalent of these transformations exists in a biological environment such as bacteria or mammalian cells. It is, therefore, only logical that recent interest has focused on developing transition-metal based catalytic systems that are capable of performing transformations inside cells, with the aim of inducing medicinally relevant cellular changes. Because unlike in stoichiometric reactions, a catalytically active compound may turn over many substrate molecules, only very small amounts of such a catalytic metallodrug are required to achieve a desired pharmacologic effect, and therefore, toxicity and side reactions are reduced. Furthermore, performing catalytic reactions in biological systems also opens the door for new methodologies to study the behavior of biomolecules in their natural state, e.g., via in situ labeling or by increasing/depleting their concentration at will. There is, of course, an art to the choice of catalysts and reactions which have to be compatible with biological conditions, namely an aqueous, oxygen-containing environment. In this review, we aim to describe new developments that bring together the far-distant worlds of transition-metal based catalysis and metal-based drugs, in what is termed "catalytic metallodrugs". Here we will focus on transformations that have been performed on small biomolecules (such as shifting equilibria like in the NAD⁺/NADH or GSH/GSSG couples), on non-natural molecules such as dyes for imaging purposes, or on biomacromolecules such as proteins. Neither reactions involving release (e.g., CO) or transformation of small molecules (e.g., ¹O₂ production), degradation of biomolecules such as proteins, RNA or DNA nor light-induced medicinal chemistry (e.g., photodynamic therapy) are covered, even if metal complexes are centrally involved in those. In each section, we describe the (inorganic) chemistry involved, as well as selected examples of biological applications in the hope that this snapshot of a new but quickly developing field will indeed inspire novel research and unprecedented interactions across disciplinary boundaries.

Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)

An updated comprehensive review to help researchers understand nanozymes better and in turn to advance the field.

Water dispersed two-dimensional ultrathin Fe(iii)-modified covalent triazine framework nanosheets: peroxidase like activity and colorimetric biosensing applications

Peroxidase mimics have attracted increasing attention as emerging artificial enzymes due to their promising applications in many fields, including bionanotechnology, sustainable chemistry, and environmental remediation. Although many types of peroxidase mimics have been successfully exploited in the past decade, the development of an innovative peroxidase mimic that does not contain noble metals, but exhibits remarkable peroxidase-like activity and low cytotoxicity still remains a major challenge in this field. Herein, we present a bulk covalent triazine framework cleavage and metal atom anchoring strategy for the synthesis of iron-modified two-dimensional covalent triazine frameworks (2D Fe-CTFs) that demonstrate excellent peroxidase-like activity. Furthermore, three kinds of colorimetric sensing platforms for sarcosine, ochratoxin A, and fluoride ions were constructed based on the intrinsic peroxidase-like activity, salt-induced coagulation, and coordination competition of the 2D Fe-CTF, respectively. This work may provide a new synthetic method for peroxidase mimics that can be used in various colorimetric sensors.

Biotransporting Biocatalytic Reactors toward Therapeutic Nanofactories

Drug-delivery systems (DDSs), in which drug encapsulation in nanoparticles enables targeted delivery of therapeutic agents and their release at specific disease sites, are important because they improve drug efficacy and help to decrease side effects. Although significant progress has been made in the development of DDSs for the treatment of a wide range of diseases, new approaches that increase the scope and effectiveness of such systems are still needed. Concepts such as nanoreactors and nanofactories are therefore attracting much attention. Nanoreactors, which basically consist of vesicle-encapsulated enzymes, provide prodrug conversion to therapeutic agents rather than simple drug delivery. Nanofactories are an extension of this concept and combine the features of nanoreactors and delivery carriers. Here, the required features of nanofactories are discussed and an overview of current strategies for the design and fabrication of different types of nanoreactors, i.e., systems based on lipid or polymer vesicles, capsules, mesoporous silica, viral capsids, and hydrogels, and their respective advantages and shortcomings, is provided. In vivo applications of biocatalytic reactors in the treatment of cancer, glaucoma, neuropathic pain, and alcohol intoxication are also discussed. Finally, the prospects for further progress in this important and promising field are outlined.

Platinum Nanoparticle-Based Microreactors as Support for Neuroblastoma Cells

Excitotoxicity is a common phenomenon in several neurological diseases, associated with an impaired clearance of synaptically released glutamate, which leads to an overactivation of postsynaptic glutamate receptors. This will, in turn, start an intracellular cascade of neurotoxic events, which include exacerbated production of reactive oxygen species and ammonia toxicity. We report the assembly of microreactors equipped with platinum nanoparticles as artificial enzymes and polymer terminating layers including poly(dopamine). The biological response to these microreactors is assessed in human neuroblastoma cell culture. The microreactors' function to deplete hydrogen peroxide (H₂O₂) and ammonia is confirmed. While the proliferation of the cells depends on the number of microreactors present, no inherent toxicity is found. Furthermore, the microreactors are able to ameliorate the effects of excitotoxicity in cell culture by scavenging H₂O₂ and ammonia, thus having the potential to provide a therapeutic approach for several neurological diseases in which excitotoxicity is observed.

Enzymes as key features in therapeutic cell mimicry

Cell mimicry is a nature inspired concept that aims to substitute for missing or lost (sub)cellular function. This review focuses on the latest advancements in the use of enzymes in cell mimicry for encapsulated catalysis and artificial motility in synthetic bottom-up assemblies with emphasis on the biological response in cell culture or more rarely in animal models. Entities across the length scale from nano-sized enzyme mimics, sub-micron sized artificial organelles and self-propelled particles (swimmers) to micron-sized artificial cells are discussed. Although the field remains in its infancy, the primary aim of this review is to illustrate the advent of nature-mimicking artificial molecules and assemblies on their way to become a complementary alternative to their role models for diverse biomedical purposes.